Form 4: Amgen VP Finance & CAO Acquires 938 Shares

Amgen's VP of Finance and Chief Accounting Officer, Matthew C. Busch, reported the acquisition of 938 shares of common stock.

Summary

• Matthew C. Busch, Amgen's VP, Finance & CAO, acquired 938 shares of Amgen Inc. common stock.
• The transaction occurred on March 3, 2026, with an acquisition price of $0 per share, indicating a grant or vesting event.
• Following this transaction, Matthew C. Busch beneficially owns a total of 4,361 shares of Amgen common stock.
• The acquired shares include 60 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which are credited to unvested RSUs and paid out in shares upon vesting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It represents a routine compensation-related acquisition of shares by an executive, which is a standard practice and does not indicate a significant shift in company prospects or strategy.

Positives

• Increased insider ownership, aligning management interests with shareholders, as Matthew C. Busch's beneficial ownership increased to 4,361 shares.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as equity grants or vesting events reported on Form 4, are common compensation practices in the biotechnology and pharmaceutical industry. These filings provide transparency into executive compensation structures and changes in insider ownership, which can be a minor indicator of management's long-term commitment to the company.

Comparison to Industry Standards

• The grant of shares at a $0 price, often tied to Restricted Stock Units (RSUs) and including Dividend Equivalents (DEs), is a standard component of executive compensation packages across major pharmaceutical and biotech companies like Pfizer, Johnson & Johnson, and Merck. This practice aims to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: The increase in insider ownership, even through a grant, can be viewed positively as it further aligns management's interests with those of shareholders.
• Employees: This transaction reflects the company's ongoing equity compensation practices, which are a key component of employee retention and motivation for executives.

Key Dates

Keywords

Amgen, AMGN, Insider Transaction, Form 4, Stock Acquisition, Matthew C. Busch, Equity Incentive Plan, Dividend Equivalents